Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2015-04-01

Summary

An observational study in patients with advanced ER+, HER2 negative breast cancer, who are treated with everolimus and exemestane in combination. The objective of the study is to assess the safety pattern of everolimus in a real world setting.

Details

• Lead Sponsor: Novartis Healthcare A/S
• Treatments: Everolimus; Exemestane; Hormones; Sirolimus